We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.ContinueLearn More X
Rentschler Biopharma SE and Leukocare AG today reported on the successful first year of their unique strategic alliance. The collaboration incorporates best-in-class formulation development in every step of the biopharmaceutical development and manufacturing process. The benefits of this combination include competitive advantages, shorter development timelines, cost savings and extra patent protection for client products. The entire manufacturing process can be made more effective. In the past year, the alliance has won several new client projects, including four with US-based companies.
Dr Frank Mathias, CEO of Rentschler Biopharma SE, commented: "The first year of this strategic alliance between Rentschler Biopharma and Leukocare was a great success and has proven our rationale to deliver best-in-class formulation throughout the biopharmaceutical value chain. By repositioning formulation as a key success factor in biopharmaceutical development, we have initiated vital discussions throughout the industry. Both existing and new clients have responded very positively to this new strategy."
"Over the past year, our alliance has received a great deal of interest and recognition for this striking approach," stated Michael Scholl, CEO of Leukocare AG. "We have been able to expand our client base, particularly in the US, and look forward to acquiring further clients and development projects in the near term. This innovative approach provides our current and future clients significant competitive advantages, enabling them to exploit the full potential of their products and markets."
Leukocare is the specialized technology partner and the exclusive formulation developer for Rentschler Biopharma’s biopharmaceutical development business. Rentschler Biopharma is the first and only CDMO to have access to Leukocare’s patented SPS® formulation technologies. As part of the original agreement, Rentschler Biopharma holds a 10% stake in Leukocare and Dr. Frank Mathias is a member of Leukocare’s Board of Directors.